A multicenter prospective registry of Borden type I dural arteriovenous fistula: results of a 3-year follow-up study

Hidehisa Nishi1,2 · Hiroyuki Ikeda1,3 · Akira Ishii1 · Takayuki Kikuchi1 · Ichiro Nakahara4,5 · Tsuyoshi Ohta4,6 · Nobuyuki Sakai7 · Hirotoshi Imamura7 · Jun C. Takahashi6,8 · Tetsu Satow6 · Tomohisa Okada9 · Susumu Miyamoto1

Received: 13 January 2021 / Accepted: 8 June 2021 / Published online: 10 October 2021
© The Author(s) 2021

Abstract

**Purpose** Although intracranial dural arteriovenous fistula (DAVF) without retrograde leptomeningeal venous drainage (Borden type I) is reported to have a benign nature, no study has prospectively determined its clinical course. Here, we report a 3-year prospective observational study of Borden type I DAVF.

**Methods** From April 2013 to March 2016, consecutive patients with DAVF were screened at 13 study institutions. We collected data on baseline characteristics, clinical symptoms, angiography, and neuroimaging. Patients with Borden type I DAVF received conservative care while palliative intervention was considered when the neurological symptoms were intolerable, and were followed at 6, 12, 24, and 36 months after inclusion.

**Results** During the study period, 110 patients with intracranial DAVF were screened and 28 patients with Borden type I DAVF were prospectively followed. None of the patients had conversion to higher type of Borden classification or intracranial hemorrhage during follow-up. Five patients showed spontaneous improvement or disappearance of neurological symptoms (5/28, 17.9%), and 5 patients showed a spontaneous decrease or disappearance of shunt flow on imaging during follow-up (5/28, 17.9%). Stenosis or occlusion of the draining sinuses on initial angiography was significantly associated with shunt flow reduction during follow-up (80.0% vs 21.7%, \( p = 0.02 \)).

**Conclusion** In this 3-year prospective study, patients with Borden type I DAVF showed benign clinical course; none of these patients experienced conversion to higher type of Borden classification or intracranial hemorrhage. The restrictive changes of the draining sinuses at initial diagnosis might be an imaging biomarker for future shunt flow reduction.

**Keywords** Dural arteriovenous fistula · Natural history · Borden type I

**Introduction**

Several studies have explored the natural history of intracranial dural arteriovenous fistula (DAVF) without retrograde leptomeningeal venous drainage (RLVD), classified

1 Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

2 Department of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

3 Department of Neurosurgery, Kurashiki Central Hospital, Kurashiki, Japan

4 Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan

5 Department of Comprehensive Strokology, Fujita Health University School of Medicine, Toyoake, Japan

6 Department of Neurosurgery, National Cerebral and Cardiovascular Center, Suita, Japan

7 Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan

8 Department of Neurosurgery, Kindai University Hospital, Osaka-Sayama, Japan

9 Department of Radiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
as Borden type I [1–5]. Most of these previous reports had indicated that the natural history of DAVF without RLVD is a benign type. Reported rates of intracranial hemorrhage, newly acquired nonhemorrhagic neurological deficit (NHND), and mortality have been extremely low: 0–1%. In addition, spontaneous occlusion of the disease has been shown to occur in 3–13% of patients. However, 0–8% of patients have displayed an angiographical conversion to RLVD.

The results of Borden type I DAVF noted above were based on retrospective case series with various observation periods, which limits the reliability of the results. Also, the more detailed time-dependent change in the disease will not become clear without prospective observation with scheduled follow-up.

Here, we report a 3-year prospective observational study of DAVF without RLVD. The purpose of the study was to reveal the detailed clinical course of Borden type I DAVF under a standard conservative treatment strategy.

Materials and methods

Patients

From April 2013 to March 2016, consecutive patients with intracranial DAVF were screened at 13 study institutions in Japan. Patient information (age, sex, neurological symptoms, and medical history) and imaging data (cerebral angiography and brain magnetic resonance imaging) were submitted to the central office at the time of screening. All the diagnoses and classifications of Borden type were confirmed by 2 independent neurointerventionists. When a disagreement occurred, a third rater was assigned and the disagreement was settled among the 3 raters. The inclusion criterion was intracranial DAVF classified as Borden type I by digital subtraction angiography. Exclusion criteria were arteriovenous shunts caused by trauma, cerebral aneurysm rupture, and arteriovenous shunts related to craniotomy. Patients for whom outpatient follow-up were not possible were also excluded.

Given the completely observational nature of the study, consent to participate in this study was obtained with an opt-out approach. The study was approved by the ethics committees of each participating institution.

Study endpoint

Patients were followed up at 6, 12, 24, and 36 months after study inclusion. At the follow-up, patients were assessed for any stroke event, neurological symptom changes, and their activities of daily living status by modified Rankin scale. In addition, all patients were scheduled to undergo brain magnetic resonance imaging (MRI) at each follow-up. When a Borden classification type conversion was suspected by symptom worsening or changes in MRI findings, a cerebral angiography was considered (decision to perform follow-up cerebral angiography was at the discretion of the treating physician). Palliative intervention was not omitted to alleviate patient symptoms, especially when the symptoms were intolerable.

The primary endpoint was death or any type of stroke during the study period. The secondary endpoints were morbidity related to the disease, the status of symptoms related to the disease, any changes related to the disease on brain MRI, conversion to a higher Borden classification type, and any intervention toward intracranial DAVF. NHND was defined as neurological symptoms, including seizure, dementia, parkinsonism, focal cortical deficits, cranial nerve palsies, trigeminal neuralgia, and cerebellar dysfunction. Orbital phenomena were not included as NHND, according to previous reports [1].

The assessment of brain magnetic resonance imaging findings

All the patients received fluid-attenuated inversion recovery, T2 star or susceptibility-weighted imaging, and time-of-flight magnetic resonance angiography (MRA); other sequences were left to the standard protocol at each institution. All the neuroimaging data were collected at the central office and assessed by 2 independent raters: a neuroradiologist (TO) and a neurointerventionalist (HN), each with >10 years of experience.

The presence of new ischemic or hemorrhagic lesions, an increase or decrease of shunt flow, and the status of venous congestion were assessed. Disagreements were settled by consensus between the 2 raters.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median with interquartile range, depending on the distribution of the variables. For comparing baseline variables and outcomes in the subgroup analyses, the Mann–Whitney U test was used for continuous variables, and the Fisher exact test was used for categorical variables. For the follow-up data, a Kaplan–Meier analysis was performed to analyze the event rate of each endpoint. Two-sided p values of <0.05 was considered to indicate statistical significance. We performed the statistical analyses with the R statistical software (version 4.0.0).
Results

Data availability

The data that support the findings of this study are available, upon reasonable request, from the corresponding author.

Baseline characteristics

During the study period, 110 patients with intracranial DAVF were screened, with 40 patients classified as Borden without RLVD (type I), 27 patients classified as Borden type II, and 43 patients classified as Borden type III.

Among the 40 patients classified as Borden I, 30 patients met the inclusion criteria and agreed to participate in the study. During follow-up, 5 patients dropped out and 25 patients (25/30, 83.3%) completed the follow-up. The mean follow-up period was 33.0 months (77.8 patient-years). Ultimately, 28 patients who were followed up more than 6 months were included in the analysis (Fig. 1).

All the patients are listed in Tables 1 and 2. The mean age was 63.6 ± 14.9 years, with 15/28 (53.6%) female. The most common disease location was the transverse-sigmoid sinus (17/28, 60.7%), followed by the anterior condylar confluence (5/28, 17.9%). Tinnitus was the most common symptom (17/28, 60.7%), followed by headache (5/28, 17.9%) and asymptomatic patients (5/28, 17.9%). Two patients had an NHND, which were higher-order dysfunction and epilepsy (2/28, 7.1%). Seventeen patients were classified as Cognard type I (60.7%) and 11 patients as type IIa (30.3%).

Primary endpoint: any death or stroke event

There were no deaths (0/28, 0.0%) and no intracranial hemorrhages (0/28, 0.0%) during follow-up. Otherwise, 1 patient had a lacunar infarction at the right corona radiata after 2 years from inclusion, which was not considered to be related to the DAVF (1/28, 3.8%) (Table 2) (Fig. 2).

Neurological symptom changes and therapeutic interventions

During follow-up, nearly 40% of the patients displayed a change in symptoms. Five patients showed spontaneous symptom improvement during follow-up (5/28, 17.9%). On the other hand, 6 patients showed symptom worsening (6/28, 21.4%); brain MRI was performed in all six cases, and three patients were further evaluated with angiography. None of the patients displayed Borden type conversion with DSA; one patient displayed increase in the shunt flow, while the other two patients displayed no apparent changes in angioarchitecture. One case of progression to higher brain

Fig. 1 Flow diagram of the patients included in this study. Among 110 patients with intracranial DAVF, 40 patients had Borden type I DAVF. At inclusion, 10 patients denied participation or were unable to participate in the outpatient follow-up. After inclusion, 2 patients dropped out and had no follow-up data. Ultimately, the data of 28 patients were analyzed.
dysfunction led to an increase in the modified Rankin scale from 1 to 4 (the morbidity case; 1/28, 3.8%).

To alleviate the neurological symptoms, neurointerventional procedures were performed in 10 patients for 12 sessions (10/28, 35.7%), and radiosurgery was performed in 1 patient once (1/28, 3.8%). After these interventions, 7 patients reached partial occlusion and 3 achieved immediate complete obliteration.

The estimated rate of symptom improvement was 19.3% per 3 years, and symptom worsening was 20.0% per 3 years (Fig. 2).

The findings on magnetic resonance imaging and cerebral angiography

All untreated patients completed the scheduled follow-up MRI until 36 months, except one patient with asymptomatic transverse-sigmoid sinus DAVF who denied MRI at the 36-month follow-up. There was no sign of intracranial hemorrhage or worsening of cortical venous congestion on T2-star-weighted images (0/28, 0.0%). During follow-up, 1 patient showed new cerebral infarction at the right corona radiata, which was mentioned above (1/28, 3.8%).

On MRA, 5 patients showed spontaneous shunt-flow reduction (5/28, 17.9%). All 5 cases were located at the transverse-sigmoid sinus, and 4 of them were preceded by spontaneous symptom improvement by 6–12 months, except for 1 asymptomatic case. Among these 5 patients, shunt flow disappeared in 2 patients on MRA (2/28, 7.1%). Clinical symptoms also disappeared in both cases. Otherwise, none of these findings was confirmed by angiography. The representative case is shown in Fig. 3.

The estimated annual rate of shunt flow reduction on MRA was 16.6% per 3 year, and shunt disappearance on MRA was 8.5% per 3 years (Fig. 2).

Subgroup analysis: comparison between patients with spontaneous shunt flow reduction and the others

The patients were divided into two subgroups according to whether shunt flow was spontaneously reduced or not during follow-up. While no apparent difference in biological backgrounds, such as patient age, sex, and comorbidities were found, the diagnostic subtraction angiography findings at initial diagnosis were different between two groups. The presence of the stenosis or occlusion of the
Table 2  The patients without spontaneous shunt flow reduction or obliteration during follow-up

| Case no | Age (years), sex | Side, location | Feeding artery                      | Draining vein                               | Stenosis or occlusion of the draining veins | Initial symptom | Spontaneous change in symptoms | Spontaneous change in MRI findings | Intervention | Clinical outcome (modified Rankin scale score) |
|---------|------------------|----------------|-------------------------------------|---------------------------------------------|---------------------------------------------|-----------------|-------------------------------|----------------------------------|--------------|------------------------------------------|
| 1       | 60, F            | Lt. TS/SS      | OA, MMA, APhA, VA                   | Internal jugular vein, Inferior petrosal sinus, transverse sinus | No                                          | Tinnitus        | No                            | No                               | No           | No                                       | 1               |
| 2       | 68, M            | Lt. ACC        | APhA, VA                            | Internal jugular vein                       | No                                          | Tinnitus        | No                            | No                               | No           | No                                       | 1               |
| 3       | 45, M            | Rt. TS/SS      | OA                                   | Sigmoid sinus                               | Yes                                         | None            | Yes, new onset of tinnitus    | No                               | No           | 0                                        |
| 4       | 71, M            | Rt. ACC        | APhA, OA                            | Internal jugular vein, sigmoid sinus         | No                                          | Tinnitus        | Yes, worsening                | No                               | No           | 1                                        |
| 5       | 78, F            | Lt. TS/SS      | OA, MMA, PAA                        | Sigmoid sinus, transverse sinus             | No                                          | Tinnitus        | No                            | No                               | Yes (TAE)    | 0                                        |
| 6       | 69, F            | Lt. CS         | MHT, inferolateral trunk            | Inferior petrosal sinus                     | No                                          | Headache, eye movement disorder             | No                            | No                               | Yes (TVE)    | 0                                        |
| 7       | 65, F            | Lt. TS/SS      | OA, MMA, PAA                        | Sigmoid sinus                               | Yes                                         | Tinnitus        | No                            | No                               | Yes (TAE)    | 0                                        |
| 8       | 74, M            | Confluence     | OA, VA                              | Transverse sinus                            | Yes                                         | Higher brain dysfunction                      | Yes, worsening    | No                               | Yes (TAE)    | 4                                        |
| 9       | 47, F            | Rt. TS/SS      | OA, MMA                             | Sigmoid sinus                               | No                                          | Tinnitus        | No                            | No                               | No           | 1                                        |
| 10      | 59, M            | Confluence     | OA, MMA                             | Occipital sinus, superior sagittal sinus, straight sinus | Yes                                         | Tinnitus        | No                            | No                               | Yes (TAE)    | 1                                        |
| 11      | 86, M            | Lt. TS/SS      | OA, MMA, VA                         | Sigmoid sinus                               | No                                          | None            | No                            | No                               | No           | 0                                        |
| 12      | 32, F            | Rt. ACC        | OA, VA                              | Internal vertebral venous plexus, cervical venous plexus | No                                          | Tinnitus        | No                            | No                               | Yes (TAE)    | 0                                        |
| 13      | 63, F            | Lt. TS/SS      | OA, MMA, STA                        | Sigmoid sinus                               | No                                          | Tinnitus, seizure | No                            | No                               | No           | 0                                        |
| 14      | 42, F            | SSS            | MMA, Ophthalmic artery (recurrent meningal artery) | Sigmoid sinus                               | No                                          | Headache        | No                            | No                               | No           | 1                                        |
| Case no | Age (years), sex | Side, location | Feeding artery | Draining vein | Stenosis or occlusion of the draining veins | Initial symptom | Spontaneous change in symptoms | Spontaneous change in MRI findings | Intervention | Clinical outcome (modified Rankin scale score) |
|---------|-----------------|----------------|----------------|--------------|------------------------------------------|----------------|---------------------------------|-----------------------------------|-------------|-----------------------------------------------|
| 17      | 58, M           | Lt. ACC        | OA, APhA, VA   | Internal jugular vein, inferior petrosal sinus | No            | Tinnitus | No                            | No                                | No          | 1                                             |
| 18      | 62, M           | Rt. TS/SS      | OA, APhA       | Sigmoid sinus, transverse sinus                  | No            | None     | Yes, new onset of tinnitus | No                                | No          | 1                                             |
| 20      | 74, M           | Rt. TS/SS      | OA, MMA, STA, deep cervical artery | Transverse sinus, sigmoid sinus | No            | Tinnitus | No                            | No                                | Yes (TAE/TVE) 2 |
| 23      | 77, F           | Lt. TS/SS      | OA, STA, PAA   | Sigmoid sinus | Yes           | Tinnitus | No                            | No                                | Yes (TAE)    0 |
| 24      | 40, M           | Rt. TS/SS      | OA, APhA       | Sigmoid sinus | No            | Headache | Yes, headache disappear (6 M), new onset of tinnitus (36 M) | No                                | No          | 1                                             |
| 25      | 78, M           | Rt. ACC        | APhA, VA, artery of the pterygoid canal | Internal jugular vein | No            | Tinnitus | No                            | No                                | No          | 1                                             |
| 26      | 67, F           | Rt. CS         | MHT, APhA      | Inferior petrosal sinus, superior petrosal sinus | No            | Eye movement disorder | No                                | No                                | Yes (TAE/TVE, radiosurgery) 0 |
| 27      | 74, M           | Rt. CS         | MHT, artery of the pterygoid canal, artery of foramen rotundum, APhA | Inferior petrosal sinus | No            | None     | No                            | No                                | No          | 0                                             |
| 28      | 76, F           | Lt. TS/SS      | MMA, OA        | Sigmoid sinus, transverse sinus | No            | Tinnitus | No                            | No                                | Yes (TAE/TVE) 1 |

TS/SS transvers sinus/sigmoid sinus, ACC anterior condylar canal, CS cavernous sinus, SSS superior sagittal sinus, MMA middle meningeal artery, AMA accessory meningeal artery, APhA ascending pharyngeal artery, OA occipital artery, VA vertebral artery, STA superficial temporal artery, PAA posterior auricular artery, MHT meningohypophyseal trunk, TAE transarterial embolization, TVE transvenous embolization
draining sinus was significantly common in the shunt-flow reduction group (80.0% vs 21.7%, \( p = 0.02 \)). The number of feeders was slightly larger in the shunt-flow reduction group, but not statistically significant (7 [3–7] vs 3 [2–4, 6], \( p = 0.10 \)).

**Discussion**

This is the first prospectively registered data on the clinical outcomes of the patients with Borden type I DAVF. In
this study, we prospectively confirmed that Borden type I DAVF shows a benign clinical course with a conservative treatment strategy, which basically involves observing patients while considering palliative interventions when the symptoms are intolerable. Nearly 20% of the patients displayed symptom improvement and spontaneous shunt flow reduction, and 7% of the cases displayed shunt flow disappearance. Symptom improvement was significantly associated with shunt flow reduction on MRA. In most cases, symptom improvement preceded the decrease in shunt flow on MRA. Although few reports have examined the relationship between symptom improvement and imaging findings, several reports have documented spontaneous occlusion. Gross et al. reported the natural history of 126 untreated patients with Borden type I DAVF and found that spontaneous obliteration occurred in 3% of the cases [4]. Shah et al. reported the clinical course of 23 patients with Borden type I DAVF, and reported that...
Type conversion to a higher Borden type classification 0/28 (0.0%)
Worsening of venous congestion0/28 (0.0%)
Disappearance of shunt flow 2/28 (7.1%)

Table 3  Clinical outcomes

| Event                                      | Count (Percentage) |
|--------------------------------------------|--------------------|
| Symptom improvement                        | 5/28 (17.9%)       |
| <1 year after inclusion                     | 3/28 (10.7%)       |
| 1–2 year after inclusion                    | 1/28 (3.6%)        |
| 2–3 year after inclusion                    | 1/28 (3.6%)        |
| Symptom worsening                           | 6/28 (21.4%)       |
| <1 year after inclusion                     | 2/28 (7.1%)        |
| 1–2 year after inclusion                    | 1/28 (3.6%)        |
| 2–3 year after inclusion                    | 3/28 (10.7%)       |
| Mortality                                   | 1/28 (3.6%)        |
| Mortality                                   | 0/28 (0.0%)        |

MRI magnetic resonance imaging

Table 4  Neuroimaging outcomes

| Event                                      | Count (Percentage) |
|--------------------------------------------|--------------------|
| Any spontaneous changes on MRI            | 7/28 (25.0%)       |
| Decreased shunt flow                      | 5/28 (17.9%)       |
| <1 year after inclusion                    | 0/28 (0.0%)        |
| 1–2 year after inclusion                   | 4/28 (14.3%)       |
| 2–3 year after inclusion                   | 1/28 (3.6%)        |
| Disappearance of shunt flow               | 2/28 (7.1%)        |
| <1 year after inclusion                    | 0/28 (0.0%)        |
| 1–2 year after inclusion                   | 2/28 (7.1%)        |
| 2–3 year after inclusion                   | 0/28 (0.0%)        |
| Worsening of venous congestion             | 0/28 (0.0%)        |
| Type conversion to a higher Borden type classification | 0/28 (0.0%)        |

1 patient obtained complete obliteration after long-term follow-up (4%) [3]. Kim et al. reported that among 99 patients with Borden type I DAVF, 12 patients displayed spontaneous occlusion (12%) [6]. Although our assessment was based on MRA, the obliteration rate was within the range of the previous reports: 3–12%.

The ability to predict spontaneous obliteration in advance can help improve the treatment strategy for Borden type I DAVF. In this study, the stenotic changes in the affected sinuses at initial diagnosis were more frequently observed in the patients with spontaneous shunt flow reduction during follow-up. This finding might suggest that the restrictive change of draining sinus is a predictor of more dynamic change in angioarchitecture and future shunt flow reduction/obliteration. In cavernous sinus lesions, the chronological and progressive restrictive changes in the affected sinus have been reported to lead to spontaneous occlusion [8, 9]. If these unidirectional changes are common to other lesions, it is not surprising that patients with stenotic changes already observed at the time of initial diagnosis are more prone to shunt occlusion in the future. On the other hand, various mechanisms have been reported to be involved in the spontaneous occlusion of the DAVF, such as thrombosis of the dural sinus, inflammatory changes, intracranial hemorrhage, dilatational changes in the venous sinus structure, and consequent hemodynamic changes [6, 10–12]. Although various interactive mechanisms must be involved in the process of spontaneous obliteration of DAVF, stenosis and occlusion of the affected sinus emerged as a biomarker to predict shunt flow reduction in DAVF in this study. Further validation in a large number of patients is needed.

On the other hand, approximately 20% of patients in our cohort displayed worsening of symptoms, but none displayed conversion to a higher type of Borden classification. The reported rate of conversion to a higher type was relatively low: 0–8%, and it is not inconsistent that there was no case of angiographically malignant conversion, given that there were only 28 cases in the entire study population [1–3, 6]. Longer follow-up is recommended, given that the type conversion may occur in a later time window: within 4–20 years after diagnosis [3].

Several reports have described symptom changes in cases of Borden type conversion. Cognard et al. reported the details of seven patients who displayed conversion to a higher type of Borden classification; they found concomitant symptom worsening in all seven patients [7]. In the study by Kim et al., symptom worsening (including appearance of new symptoms) was observed in three of the four patients with conversion to a higher type of Borden classification [6]. Shah et al. observed symptom worsening (including appearance of new symptoms) in three of the four patients with Borden type changes; on the other hand, 4 of the 21 patients who did not display type conversion also showed exacerbation of symptoms [3]. These studies suggest that symptom exacerbations may have a high sensitivity, but low specificity for a conversion to a higher type of Borden classification. In our study, too, none of the six patients with symptom exacerbations showed a type change.

The follow-up assessment of this prospective study was primarily based on clinical evaluation and MRI with specific interest in time-of-flight MRA and T2-star/susceptibility-weighted images. The sensitivity and specificity of time-of-flight MRA for the diagnosis of DAVF is reported to be relatively high: sensitivity 64–91% and specificity 80–98% [13–15]. On the other hand, the accuracy of RLVD detection with time-of-flight MRA is slightly inferior: sensitivity 58–83% and specificity 77–93% [16]. In addition, although reports on metrics like sensitivity and specificity are few, a T2-star or susceptibility-weighted image is also reported to be useful in detecting cerebral venous congestion [17, 18]. These imaging assessments with MRI are not perfect for detecting the type conversion.
of DAVF, and the question of when to move to more invasive, but the gold standard testing (angiography) is a difficult problem. As discussed earlier, if stenotic changes are already present in the affected sinus at initial diagnosis, the chance of dynamic change in the angioarchitecture in the future is higher. Although such changes in angioarchitecture lead to shunt flow reduction or obliteration in our cases, occlusive change in the draining dural sinus might lead to a worsening of Borden classification. We suggest that more careful follow-up is necessary for Borden type I patients with stenotic or occlusive changes in the affected sinus at initial diagnosis. As neuroimaging changes have been observed even at the timing of 3-year follow-up, follow-up for > 3 years is suggested for patients.

There were several limitations to this study. First, the sample size was relatively limited according to the rarity of the disease and was subject to a certain chance of type II error. Second, 17% of patients dropped out during follow-up, which could influence the reliability of the results. Third, 34% of the cases received interventions, which led to difficulty in analyzing the pure natural history of the disease. Finally, since routine angiography during the follow-up period was not planned in this study, the follow-up assessment of shunt flow was based on MRI, which led to uncertainty for the precise evaluation. Otherwise, the periodic neuroimaging data of the entire population would offer some useful information on the clinical course of the disease.

**Conclusions**

We reported the clinical outcomes of patients with Borden type I intracranial DAVF who were prospectively registered to the study. Borden type I DAVF displayed a benign clinical course; none of these patients experienced conversion to a higher type of Borden classification or intracranial hemorrhage. While both clinical symptoms and neuroimaging findings are stable in 70–75% of the patients, more than 10% of the patients displayed a tendency toward symptom improvement, and 7% of the patients displayed spontaneous shunt flow disappearance on MRA. On the other hand, 21% of the patients had worsening symptoms and 35% required palliative treatment.

According to the subgroup analysis, the restrictive changes of draining sinuses at initial diagnosis might be an imaging biomarker for future shunt flow reduction and obliteration.

**Funding** This study was supported by research grants for the Japanese Society for Neuroendovascular Therapy (JSNET).

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Informed consent** Given the completely observational nature of the study, consent to participate in this study was obtained with an opt-out approach. The study was approved by the ethics committees of each participating institution.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Satomi J, van Dijk JM, Terbrugge KG, Willinsky RA, Wallace MC (2002) Benign cranial dural arteriovenous fistulas: outcome of conservative management based on the natural history of the lesion. J Neurosurg 97:767–770
2. Gross BA, Du R (2012) The natural history of cerebral dural arteriovenous fistulae. Neurosurgery 71:594–602
3. Shah MN, Botros JA, Pilgram TK, Moran CJ, Cross DT 3rd, Chi-coine MR et al (2012) Borden-Shucart Type I dural arteriovenous fistulas: clinical course including risk of conversion to higher-grade fistulas. J Neurosurg 117:539–545
4. Gross BA, Albuquerque FC, McDougall CG, Jankowitz BT, Jadhav AP, Jovin TG et al (2018) A multi-institutional analysis of the untreated course of cerebral dural arteriovenous fistulas. J Neurosurg 129:1114–1119
5. Davies MA, Saleh J, Ter Brugge K, Willinsky R, Wallace MC (1997) The natural history and management of intracranial dural arteriovenous fistulae. Part 1: Benign lesions. Interv Neuroradiol 3:295–302
6. Kim DJ, terBrugge K, Krings T, Willinsky R, Wallace C (2010) Spontaneous angiographic conversion of intracranial dural arteriovenous shunt: long-term follow-up in nontreated patients. Stroke 41:1489–1494
7. Cognard C, Houdart E, Casasco A, Gabriellargues J, Chiras J, Merlland JJ (1997) Long-term changes in intracranial dural arteriovenous fistulae leading to worsening in the type of venous drainage. Neuroradiology 39:59–66
8. Satomi J, Satoh K, Matsubara S, Nakajima N, Nagahiro S (2005) Angiographic changes in venous drainage of cavernous sinus dural arteriovenous fistulae after palliative transarterial embolization of observational management: a proposed stage classification. Neurosurgery 56:494–502
9. Suh DC, Lee JH, Kim SJ, Chung SJ, Choi CG, Kim HJ et al (2005) New concept in cavernous sinus dural arteriovenous fistula. Correlation with presenting symptom and venous drainage patterns. Stroke 36:1134–1139

10. Awad IA, Little JR, Akarawi WP, Ahl J (1990) Intracranial dural arteriovenous malformations: factors predisposing to an aggressive neurological course. J Neurosurg 72:839–850

11. Luciani A, Houdart E, Mounayer C, Saint Maurice JP, Merland JJ (2001) Spontaneous closure of dural arteriovenous fistulas: report of three cases and review of the literature. AJNR Am J Neuroradiol 22:992–996

12. Saito A, Furuno Y, Nishimura S, Kamiyama H, Nishijima M (2008) Spontaneous closure of transverse sinus dural arteriovenous fistula: case report. Neurol Med Chir (Tokyo) 48:564–568

13. Kwon JB, Han MH, Kang HS, Chang KH (1999) MR imaging findings of intracranial dural arteriovenous fistulas: relations with presentation, location, and MR findings in 122 patients. AJNR Am J Neuroradiol 20:1031–1036

14. Pekkola J, Kangasniemi M (2011) Posterior fossa dural arteriovenous fistulas: diagnosis and follow-up with time-resolved imaging of contrast kinetics (TRICKS) at 1.5T. Acta Radiol 52:442–447

15. Amukotuwa SA, Marks MP, Zaharchuk G, Calamante F, Bammer R, Fischbein N (2018) Arterial spin-labeling improves detection of intracranial dural arteriovenous fistulas with MRI. AJNR Am J Neuroradiol 39:669–677

16. Lin YH, Wang YF, Liu HM, Lee CW, Chen YF, Hsieh HJ (2018) Diagnostic accuracy of CTA and MRI/MRA in the evaluation of the cortical venous reflux in the intracranial dural arteriovenous fistula DAVF. Neuro radiol 60:7–15

17. Nakagawa I, Taoka T, Wada T, Nakagawa H, Sakamoto M, Kichikawa K et al (2012) The use of susceptibility-weighted imaging as an indicator of retrograde leptomeningeal venous drainage and venous congestion with dural arteriovenous fistula: diagnosis and follow-up after treatment. Neurosurgery 72:47–55

18. Jain NK, Kannath SK, Kapilamoorthy TR, Thomas B (2017) The application of susceptibility-weighted MRI in pre-interventional evaluation of intracranial dural arteriovenous fistulas. J Neurointerv Surg 9:502–507

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.